JFGIW
TGTX icon

Johnson Financial Group Inc (Wisconsin)’s TG Therapeutics TGTX Stock Holding History

Johnson Financial Group Inc (Wisconsin)’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-687
Closed -$22.8K – 940
2026
Q1 		$22.8K Hold
687
– – ﹤0.01% 547
2025
Q4 		$20.5K Sell
687
-1,368
-67% -$44.7K ﹤0.01% 589
2025
Q3 		$74.2K Buy
2,055
+1,368
+199% +$45.1K ﹤0.01% 514
2025
Q2 		$24.7K Buy
+687
New +$25.6K ﹤0.01% 524
2022
Q3 		– Sell
-500
Closed -$2K – 768
2022
Q2 		$2K Buy
+500
New +$3.12K ﹤0.01% 612

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

Johnson Financial Group Inc (Wisconsin)'s TGTX Position: Q2 2026 in Review

Johnson Financial Group Inc (Wisconsin) sold out of TG Therapeutics (TGTX) in Q2 2026, closing a stake of 687 shares — an estimated $22.8K sold.

Johnson Financial Group Inc (Wisconsin) first reported a position in TGTX in Q2 2022 and held it in 5 quarters. The position peaked at $74.2K in Q3 2025. 431 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Johnson Financial Group Inc (Wisconsin) reported no remaining TG Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Johnson Financial Group Inc (Wisconsin) sold 687 TG Therapeutics shares in Q2 2026, an estimated $22.8K.
  • Johnson Financial Group Inc (Wisconsin) first reported a position in TG Therapeutics in Q2 2022 and held it in 5 quarters.
  • Johnson Financial Group Inc (Wisconsin)'s TG Therapeutics position peaked at $74.2K in Q3 2025.
  • 431 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Johnson Financial Group Inc (Wisconsin)'s 13F filing for Q2 2026, filed 10 Aug 2026.